Corticosteroids in Community-acquired Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in children hospitalized with community-acquired pneumonia.

The hypothesis is that the use of corticosteroids decreases the length of stay in children hospitalized with community-acquired pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia

NCT04451174

COVID-19

TERMINATED PHASE3

Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial

NCT00973154

Community-acquired Pneumonia

COMPLETED PHASE3

Corticosteroid Therapy for Severe Community-Acquired Pneumonia

NCT02552342

Community Acquired Pneumonia

UNKNOWN PHASE4

Community-Acquired Pneumonia : Evaluation of Corticosteroids

NCT02517489

Community Acquired Pneumonia

COMPLETED PHASE3

Supportive Treatment and Antibiotics for Mild Pediatric Pneumonia

NCT05726253

Pneumonia Pediatric Respiratory Diseases Antibiotic Use +1 more

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Community-acquired pneumonia (CAP) is a common problem in pediatric practice. The lower respiratory tract infections, particularly pneumonia, are a frequent cause of morbidity in children and is the leading cause of mortality in developing countries.

In the last 20 years, despite several research, only a small decrease in morbidity and mortality has been achieved.

Corticosteroids have an immune-modulation effect, not completely elucidated. Most likely, this effect is due to down regulation of pro-inflammatory cytokines.

We postulate that adding corticosteroids to antibiotic treatment of CAP might change the immune response and thereby reduce morbidity, leading to a decrease in patients hospital length of stay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Corticosteroid

Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day

Group Type EXPERIMENTAL

corticosteroid

Intervention Type DRUG

Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day

Control

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

corticosteroid

Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children hospitalized for community-acquired pneumonia
* 2-18 years old

Exclusion Criteria

* Pulmonary chronic disease (including asthma)
* Immunodeficiency
* Diseases wich requires corticosteroids therapy (i.e. rheumatic diseases)
* Wheezing in current disease
* Previous hospitalization (14 days prior to admission)
* Pleural effusion on admission
* Malnutrition

Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No